Latest Asx News

Aurora Energy Metals has completed the sale of its Aurora Uranium Project to Eagle Nuclear Energy, receiving A$24.2 million in equity and retaining future milestone-linked payments and royalties.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Energy World Corporation has eliminated all group-level borrowings, strengthening its balance sheet and advancing key LNG and power projects in Southeast Asia amid ongoing operational losses.

Mayfield Group Holdings has announced the acquisition of SMEC Power & Technology for up to $30 million, marking its entry into underground mining electrical infrastructure and international markets.

FortifAI Limited reported a 51% revenue decline but a 70% reduction in net loss for H1 FY26, alongside completing a major AI technology acquisition and securing $5 million in fresh capital.

Nido Education Limited reported a 3.8% increase in revenue to $169.9 million for 2025, while earnings and net profit declined. The company declared a fully franked final dividend of 2.2 cents per share, underscoring its commitment to shareholder returns despite challenging market conditions.

NEXTDC has reported a robust first half of FY26, with strong revenue and earnings growth underpinned by a surging forward order book and expanded capital expenditure plans.

betr Entertainment has extended its NAB facility agreement maturity to July 2027, reinforcing its financial flexibility and growth ambitions. This move underscores a strong partnership with NAB amid betr’s evolving wagering business.

Piche Resources announces the resignation of Managing Director Karilyn Farmer effective April 2026, with seasoned geologist Claudio Devaux appointed as country manager to ensure continuity in exploration activities.

EcoGraf Limited has completed a comprehensive update to its Bankable Feasibility Study for the Epanko Graphite Project, confirming robust financials and a production increase to 73,000 tonnes per annum. The study underpins advanced project financing and highlights significant expansion potential amid rising global graphite demand.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.